trending Market Intelligence /marketintelligence/en/news-insights/trending/e4YZTsLqRm351x3oq5g3zg2 content esgSubNav
Log in to other products

 /


Looking for more?

Contact Us
In This List

Pfizer, Astellas prostate cancer drug fails phase 4 trial

Blog

Highlighting the Top Regional Aftermarket Research Brokers by Sector Coverage

Video

COVID-19 Impact & Recovery: Healthcare Outlook for H2 2021

Blog

Corporate Credit Risk Trends in Developing Markets: A Loss Given Default (LGD) Perspective

Blog

Corporate Credit Risk Trends in Developing Markets: A Probability of Default Perspective


Pfizer, Astellas prostate cancer drug fails phase 4 trial

Pfizer Inc. and Astellas Pharma Inc.'s phase 4 study of XTANDI, plus abiraterone acetate and prednisone as compared to treatment with just abiraterone acetate and prednisone, did not meet its primary endpoint.

The primary endpoint of the trial was improvement in progression-free survival in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer, whose prostate-specific antigen has previously progressed on XTANDI.

XTANDI is approved by the U.S. FDA for the treatment of patients with metastatic castration-resistant prostate cancer.

Pfizer and Astellas jointly commercialize XTANDI in the U.S. and Astellas has responsibility for manufacturing and all additional regulatory filings globally, as well as commercializing XTANDI outside the U.S.